Podcasts about nbs

Whether you have your top hat ready or not, the SBK Betting Podcast preview of Royal Ascot is not to be missed. Ahead of next week's five-day flat racing bonanza, Tom Collins and Ross Millar are here to give you their betting tips for all the big races. Eight Group 1's and all the major talking points are covered along with handicap fancies and selections from the two-year-old races before NAPs & NBs from the Royal meeting round off the episode.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

Sabiedroto iznīcinātāji pirmo reizi Latvijas gaisa telpā notriekuši no ārzemēm ielidojušu dronu, kura dēļ no rīta bija izsludināts apdraudējums Ludzas, Balvu un Rēzeknes novadā. Drons notriekts teritorijā starp Rēzekni un Kārsavu, Nautrēnu pagastā. Latvijas austrumu novados 8. jūnija rīts atkal ir sācies nemierīgi - ar izsludinātu dronu trauksmi Ludzas, Balvu un Rēzeknes novadā. Un pirmo reizi Latvijas gaisa telpā iznīcinātājs ir notriecis no ārvalstīm ielidojušu dronu - tas noticis Rēzeknes novadā. Vairāk stāsta LSM Latgales studijas korespondente Beatrise Borise. NBS vēstīja, ka Latvijas gaisa telpā – Latgalē – NATO Baltijas gaisa telpas patrulēšanas misijas iznīcinātāji notrieca Krievijas elektromagnētiskās karadarbības rezultātā Latvijā ielidojušo ārvalstu bezpilota lidaparātu. Dronu notrieca sabiedroto iznīcinātāji no Francijas. Saskaņā ar sākotnējo informāciju īpašumi vai cilvēki pēc sprādziena nav cietuši.

On this week's blockbuster episode of the SBK Betting Podcast, the team get stuck into the Oaks, the Coronation Cup and the Derby before TC touches on the Belmont Stakes in the US. Aidan O'Brien's charges top the market in both of the Classics, but will he come out on top in both for the second year running? While in the Coronation Cup, Calandagan is set to take on another three Coolmore horses. TC then gives his expert insight into the Belmont Stakes at Saratoga before we move onto NAP & NBs from across the weekend's action.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi#epsom #thederby #theoaks #guineas #flatracing #newmarket #belmontstakes #itvracing #horseracing #horseracingbetting #racingtips #bettingtips #horsebetting #britishhorseracing #horseracingtipster #horseracingtips #horseracingtipsuk #horseracingtipsireland #horseracingpodcast #accumulator #accumulatortips #accumulatortipstoday #leopardstown #ireland #ascotraces #royalascot #horseracingevent #podcast #betting #horseriding #ascot #doncaster Hosted on Acast. See acast.com/privacy for more information.

The SBK Betting Podcast returns to your screens with four feature races plus weekend best bets. Tom Collins and Ross Millar kick off at Beverley where the two-year-olds are in the spotlight. The lads then move over to Carlisle for the rearranged Haydock card before rounding off with NAPs & NBs.00:00 - Introduction03:24 - Hilary Needler Trophy08:25 - Two Year Old Trophy11:50 - Pinnacle Stakes16:25 - Silver Bowl20:51 - NAPs & NBsDownload SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

This week's SBK Betting Podcast covers racing on both sides of the Irish Sea. Haydock's Temple Stakes is the UK's representative before the Irish take over with first the 2000 and then 1000 Guineas. Can Gstaad right the wrongs of Newmarket or will there be an upset? Tom Collins and Ross Millar round off with their NAPs and NBs with Ross picking two selections from summer jumps action which has produced winners recently. Hosted on Acast. See acast.com/privacy for more information.

「ロイヤルオーディオ、「長野オーディオフェア 2026」を6/6-7に開催。50以上のブランドが集結」　長野県松本市のオーディオショップ・ロイヤルオーディオが主催する「長野オーディオフェア 2026」が、6月6日（土）と7日（日）の2日間、長野県長野市のNBSホールにて開催される。入場は無料で、予約も不要。

NBS v premenách času: od koruny k digitálnym inováciám - 2. časť. Budatínsky park v Žiline

Ceny na benzínkach sa napriek oprave ropovodu Družba nepohli nadol. Čím dlhšie budú vysoko, tým viac sa prelejú do cien všetkého ostatného. Zdražovanie tak nielen pokračuje, ale aj zrýchľuje. Analytik v našom dnešnom videopodcaste hovorí, že nezdražie úplne všetko. Výnimkou budú napríklad sezónne potraviny. Domácnostiam odporúča šetriť, napríklad odložiť cesty, či vyskúšať carsharing.NBS predpovedá infláciu okolo štyroch percent, čo je nad priemerom eurozóny. Podľa guvernéra Petra Kažimíra by sa však inflácia v prípade pokračovania vojny mohla vyšplhať aj na sedem percent. A keďže vojna pokračuje, na hroziace zdražovanie sme sa pýtali analytika ČSOB Mareka Gábriša.Moderuje Peter Hanák.

Ceny na benzínkach sa napriek oprave ropovodu Družba nepohli nadol. Čím dlhšie budú vysoko, tým viac sa prelejú do cien všetkého ostatného. Zdražovanie tak nielen pokračuje, ale aj zrýchľuje. Analytik v našom dnešnom videopodcaste hovorí, že nezdražie úplne všetko. Výnimkou budú napríklad sezónne potraviny. Domácnostiam odporúča šetriť, napríklad odložiť cesty, či vyskúšať carsharing.NBS predpovedá infláciu okolo štyroch percent, čo je nad priemerom eurozóny. Podľa guvernéra Petra Kažimíra by sa však inflácia v prípade pokračovania vojny mohla vyšplhať aj na sedem percent. A keďže vojna pokračuje, na hroziace zdražovanie sme sa pýtali analytika ČSOB Mareka Gábriša.Moderuje Peter Hanák.

Nous avons été créés pour vivre des relations aimantes et harmonieuses, sans dissensions, confusion ou stress émotionnel. Dieu ne veut pas que nous soyons divisés, mais que nous vivions en paix les uns avec les autres. Malheureusement, rares sont ceux pour qui une telle vie est une réalité. Souvent, les conflits sèment le chaos dans les existences, laissant les êtres humains blessés et étrangers les uns aux autres. Nous pouvons être reconnaissants de ce que Jésus nous donne sa paix. Nous n'avons pas besoin de vivre des relations brisées ou conflictuelles. Nous pouvons être en paix dans chaque situation. Psaumes 34:15 nous invite à « [chercher] la paix avec ténacité » et Matthieu 5:9 à être des « artisans de paix » (NBS). Pendant que nous recherchons la paix, Dieu agit en notre faveur. Ne laissez plus des problèmes relationnels gâcher votre vie. Soyez déterminé à mettre fin aux tensions et à rechercher la paix par tous les moyens. Si vous décidez d'être un artisan de paix, vous serez surpris du changement que votre attitude produira. Père, aide-moi à être un artisan de paix. Je te remercie de ce que je ne perds plus mon temps en disputes mesquines et stupides. Dans la mesure où cela dépend de moi, et avec ton aide, je choisis de vivre des relations paisibles et harmonieuses. — Êtes-vous prêt à aller plus loin ?

After York's Dante meeting took centre stage this week, Saturday is all about Newbury. Tom Collins and Ross Millar take a deep dive into the Lockinge Stakes and the London Gold Cup before finishing off strong with their NAPs & NBs. Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

NBS v premenách času: od koruny k digitálnym inováciám - 1. časť. Na bicykli po okolí Podhájskej. Slam poetry na Slovensku

On this week's SBK Betting Podcast, Tom Collins and Ross Millar return from the first Classic weekend of the season to dive into all the action at Ascot and Lingfield. After a week which has seen plenty of movement in the Derby market, Lingfield hosts its trial for Epsom's big race. The team then move over to Ascot to cover the Victoria Cup before finishing with their NAPs & NBs.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins:X - https://x.com/TomptinFollow Ross MillarX- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarr... Hosted on Acast. See acast.com/privacy for more information.

2000 Guineas, 1000 Guineas, SBK Irish Mares Champion Hurdle and the Kentucky Derby. This week's SBK Betting Podcast has the lot. The lads kick off at Punchestown for the Mares Champion Hurdle before transitioning into Flat mode for the first of this season's Classics. The 2000 Guineas market is topped by George Boughey's Bow Echo but will TC and Ross pick him as their selection? We then move onto Sunday's 1000 Guineas before TC takes us through the Kentucky Derby and the packed undercard from Churchill Downs. As always NAPs and NBs round off this week's action-packed podcast. Don't miss it!Time Stamps00:00 - Introduction01:55 - SBK Irish Mares Champion Hurdle05:28 - 2000 Guineas12:09 - 1000 Guineas16:19 - Kentucky Derby18:53 - NAP & NBsDownload SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

The SBK Betting Podcast crew return to analyse and give their betting tips for the final weekend of the jumps season in the UK. Sam Twiston-Davies joins the pod live from the famous Twiston-Davies bus to talk us through his two rides for Saturday and review his season as a whole. Ross and TC then dive into Sandown where the Bet365 Gold Cup and the Celebration Chase top the bill. As always, NAPs & NBs round off this week's podcast.Punchestown Competition Terms & Conditions: https://help.getsbk.com/hc/en-gb/articles/35251300080669-SBK-X-Social-SBK-Festival-Finale-Day-Punchestown-Tickets-GiveawayDownload SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

??LIVE [한판승부] 송영길 연수! 김남준 계양! 전략공천 속보 긴급 분석 ◎ 1부 (18:00-19:00) [승부사들]0. 민주당, 송영길 연수갑 김남준 계양을 전략공천1. 張 “해당행위 강력한조치...후보자 교체도”2. NBS 국민의힘 15%...창당후 최저치3. 주호영 “대구시장 불출마...장동혁 대표에게 한말씀”4. 수도권 다자구도...국힘과 개혁신당 연대가능성은?5. 민주당 전략공천 향방은...거물급 인사 행보6. 김용남 하남 가남?...평택서 조국과 경쟁할수도- 강수영 변호사, 서정욱 변호사 ◎ 2부 (19:00-19:30) [한판 인터뷰]1. 대선이어 서울시장 출마선언...권영국이 그리는 서울은?2. 오세훈의 한강, 이명박의 청계천...권영국의 ‘네모’는?3. 박순관 아리셀 대표, 2심서 대폭 감형4. 울산서 진보 단일화 기류...서울은?5. 소수정당 후보로서...서울시민 설득 방안은?- 권영국 정의당 대표 ◎ 3부 (19:30-19:15) [더 라커룸]1. 민주당의 고차방적식..키는 송영길?김용남?김용?이광재?2. 국민의힘 지지율 충격....창당 후 역대 최저 15%- 박지훈 변호사, 박진영 민주연구원 부원장See omnystudio.com/listener for privacy information.

A sharp acceleration in infrastructure spending has emerged as a key pillar of China's investment stabilization drive, offsetting a persistent decline in the property sector and helping overall investment return to positive growth in the first quarter, officials and economists said.随着基础设施建设支出显著提速，我国稳投资格局初显成效。在房地产开发投资持续探底的背景下，基建领域的强劲增长有效对冲了行业下行压力，带动一季度整体固定资产投资重回正增长区间。The rebound came after authorities vowed late last year to halt the investment downturn, following a 3.8 percent contraction in fixed-asset investment in 2025.此番回暖发生在此前投资增速持续承压之后。数据显示，2025年全年固定资产投资曾收缩3.8%，有关部门于去年底明确释放了遏制投资下滑的政策信号。According to the National Bureau of Statistics, fixed-asset investment reached 10.27 trillion yuan ($1.51 trillion) in the first quarter, up 1.7 percent year-on-year. Beneath the headline figure, however, lies a sharp divergence. Infrastructure investment surged 8.9 percent, while property development investment plunged 11.2 percent.国家统计局最新公布的数据显示，今年一季度，全国固定资产投资达10.27万亿元，同比增长1.7%。尽管总量增长温和，内部结构分化却极为显著：基础设施投资同比大增8.9%，而房地产开发投资则同比下降11.2%。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said that infrastructure investment — the area where the government has the most direct leverage — has ramped up significantly at the start of the year.东方金诚首席宏观分析师王青指出，基建投资作为政府宏观调控最直接有效的抓手，在开年即展现出强劲的拉升势头。"The pace of growth in the first quarter exceeded what the market had anticipated," Wang said.“一季度的实际增速已超出此前市场普遍预期。”王青表示。China has not disclosed the scale of its infrastructure investment in recent years. However, a report by China Galaxy Securities suggests that the proportion of infrastructure investment within total fixed-asset investment has been rising, estimating it at about 45.3 percent as of end-2023.近年来官方虽未单独披露基建投资的绝对规模，但据中国银河证券研报测算，基建投资在固投总额中的占比呈逐年抬升趋势，截至2023年底，该比例约为45.3%。Last year, the sector faced significant headwinds. Due to a combination of fiscal constraints and a high base of comparison, infrastructure investment saw a rare year-on-year decline of 2.2 percent for the full year, according to the bureau.回顾2024年，该领域曾面临不小的增长阻力。受制于财政紧平衡与高基数效应的叠加影响，国家统计局数据显示，全年基础设施投资罕见录得2.2%的同比降幅。Luo Zhiheng, chief economist at Yuekai Securities, said the robust first-quarter growth accelerated by 8.3 percentage points from the full-year 2025 level and contributed 2.7 percentage points to overall investment growth.粤开证券首席经济学家罗志恒分析称，一季度基建投资增速较2025年全年大幅回升8.3个百分点，对整体投资增长的贡献率高达2.7个百分点。"Infrastructure spending countered the drag from the prolonged property downturn and served as the key factor behind the turnaround from negative growth last year," Luo said.“基建支出的放量，有效对冲了房地产长周期调整带来的拖累，是推动固投由负转正的决定性力量。”罗志恒指出。As 2026 is the inaugural year of the 15th Five-Year Plan (2026-30),"Local governments have strong incentives to create economic activities in the first year to set the foundation for the next five years of development."2026年作为第十五个五年规划的开局之年，这一加速增长具有更强的导向意义。分析认为，地方政府在五年规划首年普遍存在“抢先抓早”的能动性，意在通过重大项目落地为后续发展筑牢根基。The NBS said that in the first quarter, investment in projects with planned total investment of 100 million yuan or more rose 4.5 percent year-on-year, indicating that large-scale construction is accelerating.国家统计局数据同时显示，一季度计划总投资亿元及以上大项目投资同比增长4.5%，表明大型工程项目正处于加速建设周期。Funding has followed the projects. Luo said fiscal resources were deployed early and aggressively in the first quarter.资金的保障为项目推进提供了坚实支撑。罗志恒表示，一季度财政资源体现出了明显的“靠前发力”特征。Public bond issuance data show that in the first quarter, local governments issued about 3.1 trillion yuan in bonds, an increase of about 9.3 percent from the same period last year. Newly issued special bonds directly tied to infrastructure project construction reached about 1.2 trillion yuan, up about 25 percent year-on-year.债券发行数据印证了这一判断。一季度，各地累计发行地方政府债券约3.1万亿元，较去年同期增长约9.3%。其中，直接用于项目建设的专项债券规模约1.2万亿元，同比增幅高达约25%。The shift is not just about spending more — it is about spending differently, according to analysts.在分析人士看来，此轮发力不仅体现在投入总量的增加，更体现在投向结构的优化。While traditional rail, road and airport projects remain important, new infrastructure areas including computing centers, 5G and 6G networks, electric vehicle charging piles, and low-altitude flight infrastructure are becoming the new growth drivers, said Wen Bin, chief economist at China Minsheng Bank.中国民生银行首席经济学家温彬认为，在传统“铁公基”项目保持稳定投入的同时，算力枢纽、新一代移动通信网络、新能源充电设施及低空经济配套等新基建领域，正加速成长为驱动投资增长的新引擎。"The government is using infrastructure investment not just to stabilize growth in the short term, but to shape China's transition to a digital, green and innovation-driven economy for the future," Wen said.“当前的基础设施投资已超越单纯的短期逆周期调节功能，更多承载着推动经济向数字化、绿色化、创新驱动转型的长远战略意图。”温彬称。Entering the second quarter, with the peak of project launches coming to an end and special bond issuances normalizing, Luo cautioned that infrastructure growth may slow marginally.展望二季度，随着项目集中开工潮逐步退去，加之专项债发行节奏趋于常态化，罗志恒提醒，基建投资增速或有边际放缓的可能。"Local governments face a dual squeeze from debt servicing and falling land income. Whether infrastructure can continue to play its role as a ballast for investment will depend on policy support from the central level."“现阶段地方政府面临化债支出与土地出让金下滑的双重压力。未来基建能否持续发挥‘压舱石'作用，将在很大程度上取决于中央层面转移支付及增量政策的接续支持力度。”property sector /ˈprɒpəti ˈsektə(r)/房地产行业 halt the investment downturn /hɔːlt ðə ɪnˈvestmənt ˈdaʊntɜːn/遏制投资下滑 divergence /daɪˈvɜːdʒəns/分化；背离 plunge /plʌndʒ/暴跌；骤降 turnaround /ˈtɜːnəraʊnd/扭转；好转 inaugural year /ɪˈnɔːɡjərəl jɪə(r)/开局之年 public bond /ˈpʌblɪk bɒnd/政府债券；公债 ballast /ˈbæləst/压舱石；稳定器

China's economic growth accelerated to 5 percent in the first quarter of 2026 despite mounting external uncertainties, underscoring that the resilience of the world's second-largest economy is underpinned by its vast domestic market, officials and experts said on Thursday.Domestic demand contributed more than four-fifths of GDP growth, they said, with investment returning to positive growth and inflation picking up — a trend expected to anchor steady economic expansion in the coming months.However, analysts cautioned that the recovery in domestic demand may not yet be on firm footing, given the slowdown in household income growth and continued pressures from elevated international energy costs, highlighting the need for ramping up targeted policy support.China's GDP came in at 33.42 trillion yuan ($4.9 trillion) in the first quarter, growing 5 percent year-on-year in real terms and 0.5 percentage point faster than the fourth quarter of 2025, the National Bureau of Statistics said on Thursday."The Chinese economy got off to a good start, with main macroeconomic indicators improving and new growth drivers expanding rapidly," said Mao Shengyong, deputy head of the NBS, adding that the economy is well-positioned to maintain steady growth in the coming period.Beating market expectations, first-quarter growth was supported by improving domestic demand and resilient export growth. Retail sales, a key gauge of consumption, grew 2.4 percent year-on-year, up 0.7 percentage point from the previous quarter, the NBS said.Fixed-asset investment rose 1.7 percent year-on-year during the first quarter, reversing a 3.8 percent decline in 2025, as infrastructure spending strengthened and manufacturing investment accelerated, while the contraction in property development investment narrowed.In total, consumption and investment accounted for 84.7 percent of first-quarter GDP growth, up nearly 30 percentage points year-on-year, the bureau said, pointing to a continued shift toward a growth model driven by domestic demand.Technological and industrial innovation also provided strong support. High-tech manufacturing contributed 32.6 percent of overall industrial output growth, which is up 6.1 percent year-on-year, 1.1 percentage points faster than in the fourth quarter of 2025.Inflation has picked up as demand strengthened. Figures calculated by Japanese investment bank Nomura show that China's GDP deflator — a broad measure of price levels — improved from — 0.6 percent in the previous quarter to — 0.1 percent in the first quarter, the highest in three years."China's reflation has transitioned from hope or expectation to reality," said Xiong Yi, Deutsche Bank's chief economist for China.This trend could improve Chinese corporates' revenue and profitability and further support the recovery of investment and household income, Xiong said, with the bank upgrading the forecast for China's 2026 real GDP growth to 4.9 percent.Solid economic performance has provided support for China's stock market, with the ChiNext Index surging 3.17 percent to close at 3,626.27 points on Thursday, an 11-year high.Junjie Watkins, equity partner at Pictet Group, a Swiss financial services company, said the Chinese market offers "a degree of certainty in an otherwise uncertain environment", underpinned by its long-term development planning, improving earnings revisions and attractive valuations.Improving sentiment is also reflected in foreign direct investment trends. A report released by US consulting firm Kearney showed that China climbed two places to rank fourth globally in the firm's 2026 FDI Confidence Index, with China's leadership in artificial intelligence and its vast domestic market as key sources of appeal.Given that the first-quarter growth has laid the foundation for achieving China's annual GDP target of 4.5 to 5 percent, analysts said the likelihood of launching significant easing measures such as interest rate cuts is low in the near term, especially as rising international oil prices continue to feed through into the domestic market.However, targeted support measures may still be needed. "The external environment is becoming more complex and volatile, while the domestic imbalance between strong supply and weak demand is still acute," said Mao from the NBS, calling for more proactive and effective macro policies in the next phase.Tao Chuan, chief economist at Guolian Minsheng Securities, said that policymakers should guard against potential pressures on consumption, as the tapering of consumer goods trade-in subsidies, combined with higher energy prices, may weigh on consumption growth.Retail sales rose 1.7 percent year-on-year in March, down from 2.8 percent in the January-February period, the NBS said, while per capita disposable income grew 4 percent year-on-year in real terms during the first quarter, down by 1 percentage point from 2025.

As the jumps season draws to a close, Ross Millar is despairing and Tom Collins is jumping for joy but we still have a bit of both on this podcasts.Kicking off at Ayr, the lads dive into the Scottish Grand National and the Scottish Champion Chase before heading south to Newbury where a packed-card does not feature Constitution Hill. However, TC will give his betting tips for the Fred Darling and the Greenham Stakes before we round off with NAPs & NBs from the both of them.0-36secs - Intro00:37 - 7:31 - Sam Twiston-Davies7:32 - 11:23 - Grand National Recap11:32 - 14:45 - Scottish Champion Hurdle14:50 - 18:55 - Scottish Grand National19:23 - 20:50 Fred Darling Stakes20:51 - 26:57 - Greenham Stakes26:59 - 32:39 - NAP & NB'sPunchestown Competition Terms & Conditions: https://help.getsbk.com/hc/en-gb/articles/35251300080669-SBK-X-Social-SBK-Festival-Finale-Day-Punchestown-Tickets-GiveawayDownload SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

Breaking down both play-in matchups tonight and then poking around the other series

This week's SBK Betting Podcast has everything you need ahead of an action-packed Easter weekend. After chatting to Sam Twiston-Davies and finding out his best hope at Haydock, TC dives into AW Finals day with a selection from Newcastle and Lingfield. The lads then travel north of the border to give their betting tips for the two feature races at Musselburgh and Ross gives his two picks from Saturday's National Hunt cards. The Irish Grand National at Fairyhouse is next on the agenda before this episode is rounded off with NAPs & NBs. Hosted on Acast. See acast.com/privacy for more information.

Manufacturing rebounds, but smaller enterprises remain under pressure制造业有所回暖，但中小企业仍面临压力China's manufacturing activity returned to expansion territory in March, offering an early sign that policy support is beginning to feed through to the real economy as measures to boost demand and stabilize growth gain traction, experts said on Tuesday.3月，我国制造业活动重返扩张区间。专家3月31日表示，这为观察中国经济提供了一个早期信号，表明随着提振需求、稳定增长的措施逐步显效，政策支持正开始向实体经济传导。However, they cautioned that prolonged weakness among small and medium-sized enterprises highlights lingering structural pressures and underscores the challenge for policymakers in fostering a more broad-based recovery in the world's second-largest economy.不过专家也提醒，中小企业持续疲软凸显结构性压力依然存在，也表明政策制定者在推动我国作为世界第二大经济体实现更广泛复苏方面仍面临挑战。They also said that continued countercyclical policy support, faster rollout of major government investment projects and more targeted measures to ease financing burdens on small and medium-sized enterprises will be key to boosting orders, reviving production and underpinning a solid start to the 15th Five-Year Plan (2026-30) period.专家还表示，持续加强逆周期调节政策支持、加快重大政府投资项目落地、出台更有针对性的措施缓解中小企业融资压力，对于扩大订单、恢复生产、支撑"十五五"时期（2026-2030年）实现良好开局至关重要。Their comments came as China's official purchasing managers' index for the manufacturing sector stood at 50.4 in March, up from 49.0 in February and returning to expansion territory, according to data released by the National Bureau of Statistics on Tuesday. The subindex for production stood at 51.4 in March, up from 49.6 in February, while the gauge for new orders came in at 51.6, up 3 percentage points from the previous month, the NBS said.国家统计局3月31日发布的数据显示，3月份，我国制造业采购经理指数（PMI）为50.4%，比上月上升1.5个百分点，重返扩张区间。国家统计局表示，生产指数为51.4%，比上月上升1.8个百分点；新订单指数为51.6%，比上月上升3.0个百分点。Huo Lihui, an NBS statistician, attributed the rebound in manufacturing PMI to the faster resumption of work and production after the Spring Festival holiday, as well as increased market activity, with the production index and the new orders index both returning to expansion territory.国家统计局服务业调查中心首席统计师霍丽慧表示，制造业PMI回升主要是受春节后企业加快复工复产、市场活跃度提升等因素影响，生产指数和新订单指数均回到扩张区间。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said sentiment in China's manufacturing sector improved in March, buoyed by optimism after the recently concluded two sessions, the annual gatherings of China's top legislative and political advisory bodies, which underscored that China's macro policies would remain more proactive and effective this year.东方金诚首席宏观分析师王青表示，近期闭幕的全国两会释放出今年宏观政策将更加积极有为的信号，受此鼓舞，3月份我国制造业景气水平有所改善。That policy tone was reinforced by the People's Bank of China on Tuesday. In a statement released after the first-quarter meeting of its monetary policy committee for 2026, the PBOC said it would continue to implement a moderately loose monetary policy, step up countercyclical and cross-cyclical adjustments, and improve coordination between monetary and fiscal policies to promote stable economic growth and a reasonable recovery in prices.中国人民银行3月31日进一步强化了这一政策基调。央行货币政策委员会2026年第一季度例会指出，将继续实施适度宽松的货币政策，加大逆周期与跨周期调节力度，加强货币财政政策协调配合，促进经济平稳增长和物价合理回升。Meanwhile, major manufacturing segments strengthened further and maintained a mild upward trend. High-tech manufacturing, for instance, posted a PMI reading of 52.1 in March, up 0.6 percentage point from February, and remained in expansion territory for the 14th consecutive month, the NBS reported.与此同时，重点制造业板块进一步增强，并保持温和上升势头。国家统计局数据显示，高技术制造业PMI为52.1%，比上月上升0.6个百分点，连续14个月处于扩张区间。Despite the overall expansion, small and medium-sized manufacturers remained under pressure, with activity still in contraction territory.尽管制造业总体扩张，但中小型制造企业仍面临压力，其相关活动仍处于收缩区间。According to the NBS, the subindex for medium-sized enterprises rose 1.5 percentage points to 49.0, while that for small enterprises climbed 4.5 percentage points to 49.3, but both remained below the 50-point threshold.国家统计局数据显示，中型企业PMI为49.0%，比上月上升1.5个百分点；小型企业PMI为49.3%，比上月上升4.5个百分点，但两者均仍低于50%的临界点。"Soaring raw material prices have dealt a heavier blow to small and medium-sized enterprises, which generally have weaker pricing power and thinner financial buffers," said Bai Wenxi, vice-chairman of the China Enterprise Capital Union.中国企业资本联盟副理事长柏文喜表示，原材料价格飙升对中小企业打击更大，中小企业议价能力普遍较弱，财务缓冲能力也较为薄弱。Huang Yiping, dean of Peking University's National School of Development, said China has policy room, on both monetary and fiscal fronts, to cope with the potential economic headwinds stemming from geopolitical uncertainties in the Middle East.北京大学国家发展研究院院长黄益平表示，面对中东地缘政治不确定性可能带来的经济逆风，中国在货币和财政两方面都有政策空间予以应对。Foreign companies also remain upbeat about the long-term prospects of China's manufacturing sector.外资企业也对中国制造业的长期前景保持乐观。Markus Kamieth, CEO of German chemical company BASF, said China has moved to the forefront of intelligent manufacturing and green transformation, driven by its scale, speed and innovation capacity.德国化工企业巴斯夫执行董事会主席凯礼表示，中国凭借其规模、速度和创新能力，已在智能制造和绿色转型领域走在前列。Philippe Delorme, president and CEO of Finnish elevator giant KONE Corp, said the company's core production base in Kunshan, Jiangsu province, has grown into the world's largest elevator manufacturing base. "This figure demonstrates our commitment to China's economic growth," he added.芬兰通力集团总裁兼首席执行官德龙表示，该集团位于江苏昆山的核心生产基地已发展成为全球最大的电梯制造基地。他表示："这一事实表明了我们对中国经济增长的坚定承诺。"countercyclical /ˌkaʊntərˈsaɪklɪkəl/逆周期的purchasing managers' index /ˈpɜːrtʃəsɪŋ ˈmænɪdʒərz ˈɪndeks/采购经理指数gauge /ɡeɪdʒ/指标resumption of work and production /rɪˈzʌmpʃən əv wɜːrk ænd prəˈdʌkʃən/复工复产buoy /bɔɪ/提振；使上涨financial buffer /faɪˈnænʃəl ˈbʌfər/财务缓冲能力

¨Júlia Čillíková pôsobí ako výkonná riaditeľka úseku dohľadu a ochrany finančého spotrebiteľa NBS. Slovensko sa aj tento rok zapája do medzinárodnej kampane Medzinárodný týždeň peňazí. Ako sa doma rozprávať o financiách a ako zabezpečiť deti do budúcnosti? Miroslav Kotov je predseda Asociácie dôchodkových správcovských spoločností. Príprava na dôchodok sa začína prvou výplatou. Spoliehať sa v budúcnosti iba na štátnu dôchodkovú dávku nestačí. V rozhovore povie viac. Monika Vranková a Marek Vaňous sú zakladatelia komunity spisopriateľov, ktorí dokazujú, že písať môže naozaj každý a nikto na to nemusí byť sám. Premýšľate nad vlastnou poviedkou, románom či vydaním knihy? Inšpirujte sa ich príbehom a praktickými radami. Profesionálny iridológ Ľubomír Jánoš prezradí, čo sa dá vyčítať z našich očí – od genetiky, cez zápaly, kondíciu orgánov až po neurologické signály. Čo odhalí dúhovka, zrenička či očné bielko? A čo si dokážeme všimnúť aj sami doma? Veronika Jursová Prachárová z Inštitútu pre dobre spravovanú spoločnosť hovorí o projekte Úradnícky čin roka, ktorý tento rok vstupuje do svojho 7. ročníka. Spoznáte aj príbeh, ktorý ju osobne chytil za srdce a ukázal, že aj verejná správa môže fungovať ľudsky, efektívne a s veľkým nasadením. Muzikálový herec Lukáš Pišta chystá v divadle Nová scéna premiéru muzikálu MÜLLER – Život na 2 ťahy. Ako sa mu Richard hrá? Aj to zodpovie v rozhovore. | Hosť DRS: Júlia Čillíková, Miroslav Kotov, Monika Vranková, Marek Vaňous, Ľubomír Jánoš, Veronika Jursová Prachárová, Lukáš Pišta. | Moderujú: Gabika Angibaud a Richard Dedek. | Počúvajte rozhovory s našimi hosťami v programe Dobré ráno, Slovensko! každý pracovný deň po 8:20. Hosť DRS pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1.

With the Cheltenham Festival behind us, attention now turns to Newbury. Firstly, Ross Millar caught up with Sam Twiston-Davies, who is fresh off success last Saturday in the Midlands Grand National. Sam looks back on the big race victory and gives his thoughts on his rides this weekend. Tom Collins and Ross then dive into Saturday's card at Newbury as they tackle the two feature races before rounding off with NAPs & NBs.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

The 2026 Cheltenham Festival is in the books, so what's next? Good question, Tom Collins and Ross Millar dish out their festival awards before putting forward their ante-post selections for next year's festival and covering this weekend's racing.The Midlands National takes centre stage at Uttoxeter before the panel conclude with their NAPs & NBs.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins:X - https://x.com/TomptinFollow Ross MillarX- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

Slovensko bude súčasťou pilotného testovania digitálneho eura v praxi, ktoré je naplánované už na jeseň budúceho roka. Plná prevádzka sa očakáva v roku 2029. Pôjde o tretiu formu hotovosti popri minciach a bankovkách, pričom má mať digitálnu podobu. Rudolf Pataki, vedúci oddelenia stratégie platobných systémov Národnej banky Slovenska a expert na digitálne euro vysvetľuje, ako bude fungovať v praxi. Používateľ digitálneho eura si prevedie časť svojich peňazí z bežného účtu na špeciálny účet vo svojej banke a cez neho budeme môcť vykonávať akékoľvek platby. „Tak, ako dnes si vytiahnete hotovosť fyzicky z bankomatu a dáte si ju do peňaženky, tak v budúcnosti si prevediete peniaze do svojej digitálnej peňaženky vo forme aplikácie a budete ich môcť používať aj bez pripojenia na internet alebo mobilný signál,“ hovorí Pataki. Fungovanie v režime offline bude výhodou na miestach bez signálu, trebárs na horskej chate alebo v podzemnej garáži, kde by sa inak nedalo zaplatiť kartou alebo mobilom. „Pri digitálnom eure to nebude problém, nebudete totiž potrebovať ani mobilný signál, ani prístup k internetu,“ hovorí expert NBS. Celé technické riešenie je zabezpečené centrálnymi bankami a komunikáciu s konečnými užívateľmi už budú mať v rukách komerčné banky. Rudolf Pataki vysvetľuje, že ľudia platiaci digitálnym eurom nebudú mať účty v centrálnej banke, a tá ani nebude vidieť žiadne detaily ich platieb. Využívanie tejto novinky bude dobrovoľné a nijako neobmedzí platby v hotovosti alebo bankovými kartami a prevodmi. S projektom digitálneho eura sa spájajú aj obavy z narušenia súkromia, ale podľa Patakiho nemajú racionálny základ. „Aj za projektom okamžitých platieb sú centrálne banky, ktoré prevádzkujú tento platobný systém a predsa nevznikajú také vášnivé obavy ako pri projekte digitálneho eura.“ Prečo digitálne euro vyvoláva u časti obyvateľov taký silný odpor? „Ľudia majú málo informácií a možno by tento projekt radi torpédovali lobistické skupiny, ktoré ho vnímajú ako konkurenciu,“ hovorí expert NBS. Rozhovor moderuje Eva Mihočková. V rozhovore sa dozviete: Čo je digitálne euro a ako sa bude používať Čo znamená, že bude fungovať aj offline Aký bude limit na platbu digitálnym eurom Koľko digitálne euro ušetrí obchodníkom Ako bude fungovať ochrana súkromia platobného styku Prečo je okolo digitálneho eura toľko hoaxov See omnystudio.com/listener for privacy information.

We are just days away from the greatest show on turf, but that doesn't mean we are going to miss out covering this weekend's card at Sandown. We catch up with Sam Twiston-Davies to discuss his rides this weekend before Ross and TC dive into the Imperial Cup and The EBF Final. Before NAPs & NBs, Ross and TC create their dream seven-race card for a day at the Cheltenham Festival. Let us know how your dream Cheltenham card would line up?Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillFollow Sam Twiston-Davies: X - https://x.com/samtwiston Hosted on Acast. See acast.com/privacy for more information.

With the Cheltenham Festival is days away, the SBK Betting Podcast crew are back to give their best bets for this weekend. |TC and Ross are joined by SBK jockey Sam Twiston-Davies as they cover action from Kelso and Newbury before focussing on their NAPs & NBS for Saturday's racing.Download SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins:X - https://x.com/TomptinFollow Ross MillarX- https://x.com/rosscojmillInstagram - / rossmillarr. .Follow Sam Twiston-Davies:X - https://x.com/samtwiston Hosted on Acast. See acast.com/privacy for more information.

Ever feel like you're stuck in the "messy middle" and on the operations "hamster wheel" in your practice? If so, this one's for you. Mandy Brown joins me to talk about operational efficiency and what it really takes to run a well-functioning optometry practice.   We discuss the challenges practice owners face with delegation, the importance of hiring the right people, and developing an operational mindset that supports long-term success. Mandy also shares how virtual assistants can play a meaningful role in freeing up time, improving focus, and helping owners work more intentionally on their business rather than getting stuck in the day-to-day. We wrap up the episode with Mandy providing a very insightful NBS for listeners to consider.   Resources: Connect with Mandy on LinkedIn How one owner left his practice for 30 days—and why more owners should consider it Book a Triage call with Adam Download the Practice Owner's Financial Toolkit 20/20 Money Ultimate Financial Success Masterclass OD Mastermind Interest Form Check out Adam's new book: How to Buy an Optometry Practice   ————————————————————————————— Please rate and subscribe to 20/20 Money on these platforms Apple Podcasts Spotify ————————————————————————————— For past episodes of 20/20 Money with full companion show notes, please check out our episode archive here!   The Optometry Success Podcast  Subscribe on Apple Podcasts: https://bit.ly/4tttng6 Subscribe on Spotify: https://bit.ly/4tuf0YM 

1. Slovensko má (zatiaľ) zásoby ropy a aj alternatívy dodávok 2. Zle nastavená konsolidácia dusí ekonomiku: Slovensko čaká najslabšia päťročnica 3. NBS je v bizarnom personálnom vákuu: guvernér po mandáte, viceguvernér bez agendy 

The eyes of the racing world turn to Southwell on Friday night as Constitution Hill makes his Flat racing debut in the SBK Road To Cheltenham Novice Stakes. Tom Collins and Ross Millar are on hand to preview the big race before TC catches up with Sam Twiston-Davies to get the insight on his rides for Saturday.Kempton's Dovecote Novices' Hurdle and Ladbrokes Trophy Handicap Chase are in the spotlight before the panel move on to their NAP & NBs.Let us know if you think Constitution Hill wins and whether we will see him at Cheltenham below? Hosted on Acast. See acast.com/privacy for more information.

Welcome back to Season 9 of the Recovering Perfectionist Podcast!In this episode, Christine chats with our newest Dance Wellness Community Ambassador and first one to represent Ballet, Ian Parsons. Ian is an internationally recognized ballet educator, choreographer, and former professional dancer whose career spans elite classical performance, commercial theatre, and advanced professional training. A double graduate of Canada's National Ballet School, he completed both the Professional Ballet Program and the highly selective Teacher Training Program for Former Professional Dancers, earning the Betty Oliphant Award for Excellence in Teaching.As a performer, Ian danced with The National Ballet of Canada and Les Ballets de Monte-Carlo, working with choreographers including James Kudelka, John Neumeier, Jiří Kylián, and Jean-Christophe Maillot. His career also includes appearances in the feature film adaptation of Les Misérables, the Olivier Award–nominated West End revival of Cabaret, and the UK and European tour of Cats, with the distinction of performing at the Olivier Awards at the Royal Opera House.Following his performing career, Ian developed an extensive teaching and leadership practice across Canada, the UK, and the United States. He joined the artistic faculty of Canada's National Ballet School, where he taught across all levels of the Professional Ballet Program, from foundational training through to stage-ready repertoire. During his tenure, he created the school's formalized pas de deux curriculum and served as Manager of the International Exchange Program, overseeing international placements for more than 100 students annually. His students have gone on to perform with companies including The Royal Ballet, American Ballet Theatre, Dutch National Ballet, Boston Ballet, Stuttgart Ballet, Houston Ballet, Tulsa Ballet, The Washington Ballet, Miami City Ballet, and The National Ballet of Canada, among many others.In addition to his work at NBS, Ian has taught and choreographed for professional training programs and institutions in Canada and the UK, including Performers College, The School of Ballet Theatre UK, Chantry School, Canada's Ballet Jörgen, and the Maritime Conservatory of Performing Arts, with choreography presented by Youth America Grand Prix and conservatory-level programs across North America and Europe.Ian's teaching philosophy is grounded in classical rigor, musical clarity, and long-term dancer development. Shaped by years of institutional teaching, curriculum design, and mentorship, his work centers on maintaining uncompromising technical standards while supporting dancers as whole artists, with an emphasis on sustainability, agency, and artistic longevity. Ian is currently the Artistic Director of Ballet Theatre of Phoenix and Convergence Ballet, and is based in Phoenix, Arizona.DANCE WELLNESS COMMUNITY:Join us in the INNER CIRCLE:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://dancewellnesscommunity.com⁠⁠⁠⁠⁠⁠CONNECT WITH IAN:https://www.instagram.com/ianparsonsballet/CHRISTINE BAR NOEL:All The Things! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://beacons.ai/christinebarnoel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/recoveringperfectionistpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/dancewellnesscommunity

Vládna konsolidácia škrtí náš ekonomický rast. Problémom sú neadresné vládne výdavky, napr. plošné 13. dôchodky či sociálne benefity i pre tých, ktorí ich vôbec nepotrebujú, tvrdí exguvernér NBS Šramko. Prečo by bol odchod z EÚ pre Slovensko katastrofou a hrozí nám reálny bankrot štátu?Prvý január 2009, deň, v ktorom Slovensko prijalo novú menu a pripojilo sa tak k elitnému euroklubu. Zavedenie eura sprevádzali polemiky ohľadom konverzného kurzu, ale dôvodmi pochybností boli aj možné menové špekulácie, ktoré otvorila návšteva vtedajšieho ministra financií na jachte spolumajiteľa jednej z finančných skupín, za ktorú si vyslúžil od premiéra “žltú kartu.” Jedným z otcov Eura na Slovensku bol aj vtedajší guvernér Národnej banky Slovenska Ivan Šramko. Ako dnes jeden z otcov slovenského eura hodnotí stav slovenskej ekonomiky a aké odporúčanie by dal našej vláde pri zatiaľ neúspešnej konsolidácií verejných financií? Ako vníma exguvernér NBS to, že i napriek trom masívnym konsolidačným kolám sa vláde nedarí skrotiť rozpočtový schodok? Čo podľa neho ohrozuje našu ekonomiku a hrozí Slovensku skutočne bankrot? Ak chceme mať slušnú životnú úroveň, tak jedinou možnosťou pre nás je byť členmi EÚ a mať euro, odkazuje Ivan Šramko.Ako ovplyvní nepredvídateľná a aj agresívna politika Donalda Trumpa svetovú a aj európsku ekonomiku? Obstojí Európa pod tlakom z východu i západu a nemala by byť EÚ voči USA oveľa viac asertívna? Prospelo by Únií viac federácie no a skutočne je dnes EÚ v stave ekonomického úpadku - či je to skôr propaganda neprajníkov Únie? Verejné financie sa stali obeťou krátkodobých politických záujmov, ale je to odrazom - ako i zodpovednosťou, kultúry celej našej spoločnosti, pripomína exguvernér Centrálnej banky.Sledujete Ráno Nahlas, dnes s bývalým guvernérom NBS Ivanom Šramkom. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Vládna konsolidácia škrtí náš ekonomický rast. Problémom sú neadresné vládne výdavky, napr. plošné 13. dôchodky či sociálne benefity i pre tých, ktorí ich vôbec nepotrebujú, tvrdí exguvernér NBS Šramko. Prečo by bol odchod z EÚ pre Slovensko katastrofou a hrozí nám reálny bankrot štátu?Prvý január 2009, deň, v ktorom Slovensko prijalo novú menu a pripojilo sa tak k elitnému euroklubu. Zavedenie eura sprevádzali polemiky ohľadom konverzného kurzu, ale dôvodmi pochybností boli aj možné menové špekulácie, ktoré otvorila návšteva vtedajšieho ministra financií na jachte spolumajiteľa jednej z finančných skupín, za ktorú si vyslúžil od premiéra “žltú kartu.” Jedným z otcov Eura na Slovensku bol aj vtedajší guvernér Národnej banky Slovenska Ivan Šramko. Ako dnes jeden z otcov slovenského eura hodnotí stav slovenskej ekonomiky a aké odporúčanie by dal našej vláde pri zatiaľ neúspešnej konsolidácií verejných financií? Ako vníma exguvernér NBS to, že i napriek trom masívnym konsolidačným kolám sa vláde nedarí skrotiť rozpočtový schodok? Čo podľa neho ohrozuje našu ekonomiku a hrozí Slovensku skutočne bankrot? Ak chceme mať slušnú životnú úroveň, tak jedinou možnosťou pre nás je byť členmi EÚ a mať euro, odkazuje Ivan Šramko.Ako ovplyvní nepredvídateľná a aj agresívna politika Donalda Trumpa svetovú a aj európsku ekonomiku? Obstojí Európa pod tlakom z východu i západu a nemala by byť EÚ voči USA oveľa viac asertívna? Prospelo by Únií viac federácie no a skutočne je dnes EÚ v stave ekonomického úpadku - či je to skôr propaganda neprajníkov Únie? Verejné financie sa stali obeťou krátkodobých politických záujmov, ale je to odrazom - ako i zodpovednosťou, kultúry celej našej spoločnosti, pripomína exguvernér Centrálnej banky.Sledujete Ráno Nahlas, dnes s bývalým guvernérom NBS Ivanom Šramkom. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Tramps mīkstina retoriku pret NATO sabiedrotajiem, taču savstarpējā neuzticība saglabājas. Eksperte: Transatlantiskie strīdi kaitē Ukrainai; Krievijai tas ir izdevīgi un to var izmantot. Eiropas līderi Briselē pulcējas uz ārkārtas sanāksmi. Rīgā šodien notiek NBS industriju diena – ikgadējs pasākums, kas veltīts jaunajām tehnoloģijām aizsardzības nozarē. Šonedēļ svētki autosporta cienītājiem – pašu mājās ar Alūksnes ralliju sākas vietējā rallija čempionāta sezona, bet šodien Montekarlo apkaimē ar pirmajiem ātrumposmiem startē pasaules rallija čempionāts. Pēc 20 gadu pārtraukuma Latvijā izdota jauna Sarkanā grāmata.

Slovensko prežíva zlé ekonomické časy, vláde sa nedarí vytiahnuť z firiem viac peňazí na daniach a rast HDP v tomto roku môže podľa NBS klesnúť na 0,6%, hoci ministerstvo financií verí, že to bude aspoň 1,3%. Juraj Karpiš, finančný analytik INESS a autor kníh o investovaní, analyzuje nepredvídateľný ekonomický vývoj doma aj v USA. Donald Trump stupňuje agresivitu a colnú vojnu, ale prudký prepad finančných trhov by ho vedel zastaviť v jeho deštruktívnej politike. „Má to svoje rácio, veď už sme to raz zažili,“ hovorí Karpiš. „Keď Trump ohlásil v apríli obrovské clá najmä na Činu, trhy sa prepadli o 20%. Americký minister financií vtedy Trumpovi vysvetlil, že to spolu súvisí a tak rýchlo oznámil 90-dňovú pauzu. Vtedy sa trhy spamätali, lebo pochopili, že Trump je slabý a ustúpil.“ Na trhoch sa už skutočne začal fenomén „debasement trade“, keď sa investori odkláňajú od dolára a preferujú aktíva odolné voči devalvácii. „Ľudia sa začali báť Ameriky a kapitál sa sťahuje z dolárových dlhopisov a aktív, tie strácajú na sile a hore letí zlato,“ upozorňuje analytik. Zlato skutočne za minulý rok zvýšilo svoju hodnotu o 70%, čo najprudší rast za posledných 50 rokov. Podľa Karpiša je to varovný signál, že je zle. „Za posledné dva roky vidíme najväčší nárast hodnoty zlata v modernej histórii. Je to indikátor, že prežívame zlé ekonomické a politické scenáre.“ Aktuálne dianie skresľuje pohľad investorov. „Ľudia sa často pozerajú na svoje výnosy a vravia si, že americké akcie im zarobili 20%. Ale v skutočnosti sledujú len oslabenie amerického dolára. Ak si to premenia na eurá, tak sú na nule a v českých korunách sú v mínuse,“ vysvetľuje analytik. Dodáva, že stále sme len na začiatku tohto procesu a naplno sa môže prejaviť po máji 2026, keď sa skončí mandát súčasnému šéfovi FEDu a ukáže sa, či Donald Trump dokáže presadiť svoju politiku nízkych úrokových sadzieb. Juraj Karpiš zároveň približuje, ako funguje kryptomena stablecoin, ktorá má potenciál vytvoriť celý nový sektor a vziať bankám veľkú časť trhu. „Ak ho nezakážu, môže vyvolať revolúciu v platobnom styku.“ Ako sa v tomto svete má zachovať slovenský investor? Pozrite si celý diel relácie Index s Jurajom Karpišom. Moderuje Eva Mihočková. V rozhovore sa dozviete: Vyhýbajú sa firmy plateniu daní, alebo už skrátka nevládzu? Môžu Donalda Trumpa zastaviť finančné trhy? Prečo sa investori začali báť amerických dlhopisov Prečo zlato narástlo o 70% Ako Amerika ničí sama seba a postavenie dolára Ako sa dajú využiť stablecoiny See omnystudio.com/listener for privacy information.

China's economy demonstrated strong resilience in 2025, with growth holding firm despite mounting external pressures and internal structural adjustments, while new growth drivers are taking shape to support sustainable expansion going forward, said officials and experts.政府工作人员和专家指出，2025年中国经济展现出强劲韧性，在外部压力不断加剧和内部结构调整的双重背景下，经济增长依然保持稳健，同时新的增长动力正在形成，为未来可持续扩张提供支撑。Official data released on Monday showed that China's gross domestic product grew 5 percent last year, meeting the country's annual target of around 5 percent. The hard-won performance, achieved amid heightened tariff pressures, has laid a solid foundation for a steady start to economic growth in 2026, reinforcing confidence that the world's second-largest economy remains on a stable trajectory.官方周一公布的数据显示，中国去年国内生产总值增长5%，实现了约5%的年度增长目标。在关税压力加剧的背景下取得的这一来之不易的成绩，为2026年经济增长平稳开局奠定了坚实基础，增强了市场信心，表明这个全球第二大经济体仍保持着稳定发展态势。As China enters the opening year of its 15th Five-Year Plan (2026-30) period, economists said policymakers are set to press ahead with front-loaded fiscal support to boost domestic demand, alongside a moderately accommodative monetary stance aimed at lifting prices and easing financing costs.随着中国迎来第十五个五年规划（2026-2030年）的开局之年，经济学家指出，政策制定者将推进前置性财政支持以提振内需，同时采取适度宽松的货币政策立场，旨在提振物价并降低融资成本。The country's annual GDP came in at 140.19 trillion yuan ($20.13 trillion) in 2025, according to the National Bureau of Statistics. In the fourth quarter of 2025, the Chinese economy grew 4.5 percent year-on-year, following 4.8 percent growth in the third quarter.国家统计局数据显示，2025年中国国内生产总值（GDP）达140.19万亿元（合20.13万亿美元）。2025年第四季度，中国经济同比增长4.5%，此前第三季度增速为4.8%。Kang Yi, head of the NBS, said that the latest indicators fully demonstrate the Chinese economy's steady progress, resilience under pressure, and vitality in moving toward higher-quality and innovation-driven development.国家统计局局长康义表示，最新指标充分展现了中国经济稳步前进的态势、在压力下的韧性，以及在迈向更高质量、创新驱动发展道路上的活力。"China's average annual contribution to global economic growth stood at around 30 percent throughout the 14th Five-Year Plan (2021-25) period. With a complete industrial system, China has played a stabilizing role in global supply chains and injected much-needed stability into a world economy undergoing turbulence and transformation," he said.中国在“十四五”规划（2021-2025年）期间，对全球经济增长的年均贡献率保持在30%左右。凭借完整的产业链体系，中国在全球供应链中发挥着稳定器作用，为动荡转型中的世界经济注入了急需的稳定力量。Guan Tao, global chief economist at BOCI China, said that China's economy has delivered "hard-won" results in 2025, featuring breakthroughs in technological advances and emerging consumption phenomena, setting the stage for a 2026 GDP growth target possibly at 4.5 percent to 5 percent.中银证券全球首席经济学家管涛表示，2025年中国经济取得“来之不易”的成果，技术进步实现突破性进展，消费呈现新形态，为2026年GDP增速目标设定4.5%至5%的区间奠定基础。"In 2025, when people talked about China, things like DeepSeek, Ne Zha 2, Unitree humanoid robots, the overseas expansion of innovative pharmaceuticals, and Jiangsu Football City League, or Suchao, all showed that China's economy has been full of highlights, whether in consumption recovery or technological innovation," Guan said.管涛表示：“在2025年，当人们谈论中国时，话题转向了诸如DeepSeek、《哪吒2》、宇树人形机器人、创新药出海、江苏城市足球联赛‘苏超'等新事物；焦点无论是消费复苏还是科技创新，都展现出中国经济的亮点纷呈；都无不印证着中国经济的蓬勃生机。”Citing the latest indicators, Sheana Yue, a senior economist at British think tank Oxford Economics, said that the fourth quarter's continued momentum appeared to be driven by stronger industrial activity and exports in December, which offset still weak domestic demand.英国智库牛津经济研究院高级经济学家岳喜娜援引最新指标指出，第四季度经济持续增长的动能似乎源于12月工业活动和出口的强劲表现，这抵消了国内需求依然疲软的影响。NBS data showed that China's value-added industrial output rose 5.2 percent in December, following 4.8 percent growth in November.国家统计局数据显示，中国12月工业增加值同比增长5.2%，高于11月的4.8%增速。"Our estimates suggested high-tech manufacturing, including transport equipment, electrical machinery and electronics manufacturing, continued to outperform at the end of 2025," Yue said.岳喜娜：“我们的估算显示，包括运输设备、电机和电子制造在内的高科技制造业，在2025年底仍保持着强劲增长态势。”According to the NBS, retail sales, a key indicator of consumer spending, increased 0.9 percent in December, while China's fixed-asset investment decreased 3.8 percent in 2025.据国家统计局数据显示，作为消费支出重要指标的零售额在12月增长0.9%，而2025年中国固定资产投资同比下降3.8%。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said that looking ahead to 2026, the impact of high tariffs imposed by the United States on global trade and China's exports is expected to become more pronounced, weakening the contribution of external demand to economic growth and requiring domestic demand to step in more decisively.东方金诚首席宏观分析师王青表示，展望2026年，美国高关税对全球贸易和中国出口的影响预计将更加显著，这将削弱外需对经济增长的贡献，需要内需更果断地接棒。"We expect that, with more proactive and effective macroeconomic policies continuing to gain strength, consumption will accelerate further in 2026, and investment will stabilize after bottoming out," he said.王青表示：“随着更积极有效的宏观经济政策持续发力，预计2026年消费将进一步加速增长，投资将在触底后趋于稳定。”With 2026 marking the opening year of China's 15th Five-Year Plan, Xu Hongcai, deputy director of the economic policy committee of the China Association of Policy Science, said that ensuring a smooth economic start will be critical, and called for stable, consistent and moderately forceful macro policies.2026年标志着中国第十五个五年规划的开局之年。中国政策科学研究会常务理事、经济政策委员会副主任徐洪才指出，确保经济平稳开局至关重要，呼吁实施稳定、连贯且力度适中的宏观政策。Fiscal policy should remain proactive, he said, suggesting that the fiscal deficit ratio remain at around 4 percent, supported by the continued issuance of long-term treasuries to boost consumption, improve public well-being and mitigate local government debt risks. He added that monetary policy should stay moderately accommodative, with room for further cuts to interest rates and the reserve requirement ratio.徐洪才表示，财政政策应保持积极，建议财政赤字率维持在4%左右，同时继续发行长期国债以提振消费、改善民生并缓解地方政府债务风险。他还指出，货币政策应保持适度宽松，存在进一步下调利率和存款准备金率的空间。Going forward, Xu said that China's economic growth in 2026 is expected to remain within a reasonable range, with improving quality, a more optimized structure and steady progress toward high-quality development.徐洪才表示，展望未来，2026年中国经济增长预计将保持在合理区间，质量不断提升，结构持续优化，朝着高质量发展稳步迈进。Choi Yong-ho, chief executive officer and chief happiness officer of South Korean entertainment technology company Galaxy Corp, said China's market holds virtually unlimited development potential. "It is creative, innovative and dynamic, and it is already at the global forefront in multiple industries."韩国娱乐科技独角兽Galaxy Corp首席执行官兼首席幸福官崔龙湖表示，中国市场蕴藏着几乎无限的发展潜力。“这个市场充满创造力、创新精神和活力，已在多个行业处于全球领先地位。”"China's strong capabilities in robotics and artificial intelligence are leading industrial development, and its younger generation represents a highly capable and promising talent base. With these advantages, I believe the Chinese market will continue to grow, with a very optimistic outlook," he said.崔龙湖表示：“中国在机器人和人工智能领域的强大实力正引领着工业发展，其年轻一代代表着一支能力出众、充满希望的人才队伍。凭借这些优势，我相信中国市场将继续增长，前景非常乐观。”humanoid robot/ˈhjuː.mə.nɔɪd/n.人形机器人trajectory/trəˈdʒek.tɚ.i/n.轨道；态势

Besprochene Urteile1. Strafrecht: Gefälschtes Innenministerin-Foto – erst Verurteilung, dann FreispruchAG Bamberg, Urteil vom 08.04.2025 – 27 Cs 1108 Js 11315/24 (2) LG Bamberg, Urteil vom 14.01.2026 – 11 NBs 1108 Js 11315/24Manipuliertes Foto von Nancy Faeser mit Text "Ich hasse die Meinungsfreiheit" – AG verurteilte zu sieben Monaten Bewährung wegen Verleumdung (§ 188 StGB), LG sprach frei. 2. Waffenrecht: Einkürzen einer Handfackel ist unerlaubter Umgang mit ExplosivstoffenOLG Hamm, Beschluss vom 13.01.2026 – (Az. nicht veröffentlicht)Wer Griffstück einer Handfackel von 120 mm auf 4 mm kürzt, geht unerlaubt mit explosionsgefährlichen Stoffen um. 3. Gaststättenrecht: Shishabar darf keine Shishas mehr servierenVG Mainz, Beschluss vom 29.12.2025 – 1 L 693/25.MZUntersagung der Shisha-Zubereitung trotz bestehender Gaststättenerlaubnis zulässig bei jahrelangen Sicherheitsverstößen. 4. Polizeirecht: Schmerzgriff-Urteil rechtskräftig – aus formalen GründenOVG Berlin-Brandenburg, Beschluss vom 08.01.2026 – OVG 6 N 63/25Berufungszulassung der Berliner Polizei abgelehnt – VG-Urteil zu unverhältnismäßigem Schmerzgriff gegen "Klimakleber" rechtskräftig. 5. Zivilprozessrecht: Truhe im Hausflur als wirksame ZustelladresseLG Lübeck, Urteil vom 18.12.2025 – 15 O 191/24Jahrzehntelange Praxis der Postablage auf Truhe im Hausflur ist wirksame Ersatzzustellung nach § 180 Satz 1 ZPO – auch bei Mitnutzung durch Dritte. Postbote legte seit Jahrzehnten im Einvernehmen Post auf Truhe im nicht verschließbaren Vorraum. Support the show

1. Centrálne banky pritvrdzujú pri investičných hypotékach. Signály vysiela už aj NBS 2. Po Američanoch a Európskej komisii utajovanú dohodu s USA o novej atómke definitívne potvrdila aj vláda 3. Akcie zbrojárskych firiem vlani predbehli aj sektor AI. Európa zbrojí a potrebuje na to kapitál 4. Krátko o pripravovanej zábezpeke pri registrácii na DPH, zakladaní a zánikoch firiem a o nových zelených úveroch dotovaných z eurofondov

China's consumer inflation accelerated to its fastest pace in nearly three years in December, official data showed on Friday, signaling a stabilizing economy as recent stimulus measures continued to bolster domestic demand.Going forward, analysts said consumer inflation is expected to remain mild through 2026, leaving ample room for policymakers to step up macroeconomic adjustment to counter mounting uncertainties. Policy options include targeted measures to boost domestic demand and support innovation, as well as further cuts to the reserve requirement ratio and interest rates.The country's consumer price index, the main gauge of inflation, rose by 0.8 percent year-on-year in December, following a 0.7 percent rise in November, marking the highest level since February 2023, the National Bureau of Statistics said on Friday."China's latest consumer inflation data points to a continued strengthening in domestic demand, mainly driven by the impact of consumption-boosting policies and the release of demand ahead of the New Year holiday," said Tang Guang hua, an analyst at Shen yin & Wan guo Futures Co. "Meanwhile, the core CPI remained above 1 percent for four consecutive months in December, highlighting a steady improvement in consumption fundamentals."The improving inflation data has reflected the growing momentum of the Chinese economy, with the World Bank, the International Monetary Fund and the Asian Development Bank having raised their growth forecasts for China's economy.The IMF forecasts a 5 percent GDP expansion in 2025 and 4.5 percent for 2026, while Goldman Sachs said this week that it expects China's GDP to grow 4.8 percent in real terms in 2026, supported by a policy-backed investment rebound, the potential of service consumption, resilient export growth and a milder drag of the property sector.With economic momentum showing signs of improving, Chinese stocks moved higher on Friday, with the Shanghai Composite Index posting a solid gain of 0.92 percent to close at 4,120.43 points, topping the psychologically important 4,100 points to reach a decade high. Since the beginning of the year, the index has risen by 3.82 percent, indicating a continuous improvement in investor confidence.NBS data showed the core CPI, which excludes volatile food and energy prices and is deemed a better gauge of supply-demand conditions, rose 1.2 percent year-on-year in December, unchanged from November.Meanwhile, China's producer price index — which measures factory-gate prices — fell by 1.9 percent year-on-year in December, narrowing from a 2.2 percent drop in November, the NBS said.Tang from Shenyin & Wanguo Futures Co said the narrowing decline in factory-gate prices showed strengthening recovery momentum, signaling both improving industrial fundamentals and deeper structural optimization.He expects consumer prices to rise steadily on the back of continued consumption recovery and policy support, while PPI recovery momentum is set to strengthen further given the progress in building a unified national market, industrial restructuring and rising demand from emerging industries as key drivers, particularly for high-end manufacturing.As the NBS is set to release the economic indicators for December and the fourth quarter later this month, Li Chao, chief economist at Zheshang Securities, said China's economic growth is expected to have remained resilient toward the end of 2025, fueled by relatively strong production and a gradual recovery in demand.He said that economic activity likely picked up in December, with both domestic and external demand gradually improving and companies pushing to meet year-end targets. "That will help support China to achieve its full-year growth target of around 5 percent in 2025, while laying the groundwork for a strong start in 2026."During the recently held 2026 work conference of the People's Bank of China, the country's central bank said it will continue to implement an appropriately accommodative monetary policy in 2026, underscoring its commitment to supporting high-quality economic development and promoting a reasonable rebound in prices.Li from Zheshang Securities said his team expects a 50 basis-point cut in the RRR and a 10 basis-point reduction in policy interest rates over the year.Li added that structural policy tools are expected to continue to play a key role, alongside stronger credit guidance to channel funding toward priority areas.Expanding domestic demand, advancing technological innovation and supporting micro, small and medium-sized enterprises are likely to remain the main focus of policy support in 2026, he said.

In this hour of VSiN By The Books, hosts Jensen Lewis and Dave Ross recap yesterday's top sports headlines. Plus, the guys break down their week 18 survivor leans. Also, don't miss today's edition of the “Daily Gridiron", as Jensen and Dave find different ways to attack the football market. Get instant access to expert picks, public betting splits data, and pro betting tools when you join VSiN pro. Grab your first month for only $9.99 or take over 15% off an annual subscription when you use promo code: POD25. Click Here to get started. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Almost every business owner knows they need to spend time working ON and not just IN their business. But what does it mean to take that concept to a whole new level by traveling and spending time outdoors with colleagues and strategic partners? Whether you choose to take time out of your business to work on your business and do it across town or across the country, this conversation with Drs. Julie Helmus, OD and Paul Mormon, OD talk about what it takes and means to truly invest in yourself by finding your tribe and community. This is also a perfect time to remind you, the listener, that in addition to sharing what Paul has created with GRT, the concepts and benefits we're discussing in today's episode are what we are striving to accomplish with OD Masterminds (link in the show notes). The important NBS for you: find your tribe and structure that fits you best—and helps you make progress.   Resources: Book a Triage call with Adam Download the Practice Owner's Financial Toolkit 20/20 Money Ultimate Financial Success Masterclass OD Mastermind Interest Form GRT Summit PERC IDOC   ————————————————————————————— Please rate and subscribe to 20/20 Money on these platforms Apple Podcasts Spotify ————————————————————————————— For past episodes of 20/20 Money with full companion show notes, please check out our episode archive here!

Show Notes: Shifting political priorities and economic pressures over the past couple of years have seen several countries scale back climate commitments contributing to the growing gap between climate pledges and real-world emissions (still rising).What does this mean for a ‘Just Transition' and Net Zero? While there is no silver bullet, IUCN and UNEP emphasise Nature based Solutions (NbS) can be pivotal for climate mitigation and adaptation, when pursued alongside rapid decarbonisation globally.To discuss NbS, and climate change I recently caught up with Swapan Mehra a global leader in climate action and ecosystem conservation. In this deeply insightful conversation Swapan spoke about how NbS is a holistic approach to addressing the climate crisis, through a spectrum of actions designed to protect and restore ecosystems while simultaneously delivering co-benefits for biodiversity, communities and individuals. We also spoke about…

China's industrial profits grew at its fastest pace in nearly two years in September, official data showed on Monday, as policy measures to rein in rat-race competition helped ease pressure on manufacturers despite lingering domestic and external headwinds.官方数据于周一显示，尽管国内外不利因素仍存，但随着遏制无序竞争的政策措施帮助缓解了制造商的压力，9月中国工业利润增速达到近两年来的最高水平。Analysts attributed the rebound in corporate profitability to firmer prices and resilient industrial output, supported by Beijing's pro-growth policies, pointing to a stabilizing economy buoyed by the strong performance of the new quality productive forces.分析师认为，在国家稳增长政策的支撑下，产品价格趋稳以及工业产出保持韧性，推动了企业盈利能力的回升。他们指出，得益于新质生产力的良好发展态势，中国经济正趋于稳定。Looking ahead, they expect the recovery momentum to extend into the fourth quarter, with policymakers likely to intensify countercyclical adjustments to boost domestic demand, spur market confidence and reinforce internal growth drivers — keeping China on track to meet its full-year growth target.展望未来，分析师预计复苏势头将延续至第四季度。政策制定者可能会加大逆周期调节力度，以扩大内需、提振市场信心并强化内生增长动力，确保中国能够实现全年经济增长目标。China's industrial enterprises with an annual revenue of at least 20 million yuan ($2.8 million) saw their total profits soar 21.6 percent year-on-year in September, following a 20.4 percent jump in August, marking the largest gain since November 2023, data from the National Bureau of Statistics showed on Monday.国家统计局周一发布的数据显示，9月，年营业收入2000万元（约合280万美元）及以上的中国工业企业，其实现利润总额同比激增21.6%；8月该指标同比增幅为20.4%。这意味着9月工业利润增幅创下2023年11月以来的最高纪录。During the first nine months of the year, profits at major industrial companies grew to 5.37 trillion yuan, a year-on-year increase of 3.2 percent, following a 0.9 percent rise in the first eight months.今年前9个月，规模以上工业企业实现利润5.37万亿元，同比增长3.2%；前8个月该指标同比增幅为0.9%。Wen Bin, chief economist at China Minsheng Bank, said: "The strong growth in September's industrial profits was largely driven by a low base from last year, combined with stabilizing production, easing price pressures and improving profit margins."中国民生银行首席经济学家温彬表示：“9月工业利润的强劲增长，很大程度上得益于去年同期的低基数效应，同时也受到生产企稳、价格压力缓解以及利润率改善等因素的综合推动。”NBS data showed China's industrial output surged 6.5 percent year-on-year in September after a 5.2 percent rise in August, marking the first acceleration in three months.国家统计局数据显示，9月中国工业增加值同比增长6.5%，较8月的5.2%有所提升，这是该指标近三个月来首次出现增速加快。Meanwhile, China's producer price index — which measures factory-gate prices — fell 2.3 percent year-on-year in September, easing from a 2.9 percent drop in August.与此同时，9月中国工业品出厂价格指数（PPI，衡量工厂端产品价格水平）同比下降2.3%，降幅较8月的2.9%有所收窄。Wen also noted that "structural bright spots are a key part of the rebound in corporate profitability", underpinned by the robust performance of high-tech manufacturing and equipment manufacturing sectors.温彬还指出，“结构性亮点是企业盈利能力回升的关键因素”，而高新技术制造业和装备制造业的强劲表现为这一亮点提供了支撑。According to the NBS, profits in high-tech manufacturing industries surged 26.8 percent in September, driving overall industrial profit growth to accelerate by 6.1 percentage points.国家统计局数据显示，9月高新技术制造业利润同比激增26.8%，拉动全部工业利润增速加快6.1个百分点。For the first nine months, profits in equipment manufacturing industries soared 9.4 percent, contributing 3.4 percentage points to overall profit growth.今年前9个月，装备制造业利润同比大幅增长9.4%，对全部工业利润增长的贡献率达到3.4个百分点。Citing the faster profit growth among private sector and foreign companies, Wen said that it indicates market expectations are improving, and business confidence is recovering.温彬提到，私营企业和外资企业利润增速加快，这表明市场预期正在改善，企业信心逐步恢复。Looking ahead, he said the fourth quarter will likely see steady growth in industrial profits with the government's effective measures to curb involution competition, easing price pressures and improving corporate profitability.他表示，展望未来，随着政府采取有效措施遏制行业内卷、价格压力进一步缓解以及企业盈利能力持续改善，第四季度工业利润有望保持稳定增长。In the communique of the fourth plenary session of the 20th Central Committee of the Communist Party of China, which was released on Thursday, policymakers called for "resolutely achieving the economic and social targets set for this year", suggesting they will ensure GDP growth will reach the "around 5 percent" growth target.中共二十届四中全会公报于周四发布，其中政策制定者提出“坚决完成今年经济社会发展目标任务”，这一表述意味着政府将确保国内生产总值（GDP）实现“5%左右”的增长目标。Lu Ting, chief China economist at Nomura, said he expects the country to refocus on short-term growth stability. "Beijing just needs around 4.2 percent GDP growth in the fourth quarter to deliver that target. So, from a statistics perspective, it's easily within reach," he said.野村证券首席中国经济学家陆挺表示，预计中国将重新聚焦短期经济稳定增长。他指出：“要实现全年增长目标，中国第四季度GDP增速只需达到4.2%左右即可。因此，从统计角度来看，这一目标触手可及。”The best strategy is to resist the temptation to fuel the stock markets by avoiding too high-profile monetary measures in the near term, remaining vigilant by avoiding contractionary policies, cleaning up the property market problem, and addressing some deep-rooted problems such as the unequal social security system, Lu said.陆挺认为，当前最佳策略是：短期内避免推出过于高调的货币政策，抵制刺激股市的诱惑；保持警惕，不采取紧缩性政策；着力解决房地产市场问题；并应对一些深层次问题，如社会保障体系不均衡等。A report released by the Chinese Academy of Social Sciences' Institute of Finance & Banking on Monday noted that insufficient effective demand remains a prominent challenge.中国社会科学院金融研究所周一发布的一份报告指出，有效需求不足仍是当前面临的突出挑战。Against the backdrop of US-China trade friction and profound structural economic shifts, the report said China should advance macroeconomic governance system innovation that addresses both existing structures and new growth drivers, with a focus on enhancing policy efficacy.报告称，在美国对华贸易摩擦以及国内经济结构性深刻调整的背景下，中国应推进兼顾现有结构与新增动力的宏观经济治理体系改革，并重点提升政策实施效果。"In the short term, macro policies should be proactively strengthened, including more forceful fiscal spending tilted toward consumption stimulation, utilizing the room for interest rate cuts and reserve requirement ratio reductions created by the US Federal Reserve's move, and implementing multi-pronged measures to stabilize the property market and foster its high-quality development," said Wang Qing, assistant researcher at the institute.该研究所助理研究员王青（音译）表示：“短期内，应积极加大宏观政策力度，包括采取更有力的财政支出措施并向刺激消费倾斜、利用美联储政策调整所带来的降息降准空间，以及通过多方面举措稳定房地产市场、推动其高质量发展。”resilient/rɪˈzɪliənt/adj.能快速恢复的，具韧性的countercyclical/ˌkaʊntəˈsaɪklɪkl/adj.反经济周期的

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Tretia konsolidácia Ficovej vlády ohrozila sociálny zmier. Proti konsolidácii aj rozpočtu protestujú odborári aj opozícia. Vláda zmrazila trináste dôchodky a Smer navyše hovorí o ich adresnosti. Stámilióny na energopomoc nemôže vláda zaplatiť z eurofondov. Konsolidácia dostáva trhliny a neverí je ani Národná banka.Čo s tým urobí vládny Hlas a čo chce urobiť s tým, že mu už rok padajú voličské preferencie? Prečo je podľa premiéra Peter Kažimír zradca a prečo NBS neverí vládnej konsolidácii? A čo hovorí Hlas na nápad premiéra posunúť voľby do obcí, miest a krajov o ďalší rok? Aký je na to vlastne dôvod?Braňo Závodský sa rozprával s ministrom práce sociálnych vecí a rodiny a podpredsedom strany Hlas – SD Erikom Tomášom.

Yesterday, Building and Construction Minister Chris Penk announced changes to the earthquake-prone building regulations that will remove nearly 3000 buildings from the classification register.   Previously, buildings would have to meet a 34%NBS (new building standard) threshold to predict likelihoods of withstanding seismic action. The new system instead prioritises identifying structures that pose a higher risk to human life. Alterations seek to measure risk in a manner that balances safety with more affordable and realistic remediation action for existing properties.   Producer Jasmine Gray spoke to Dr. Megan Boston, Senior Lecturer for Civil Engineering, at the University of Waikato about what the new quake-prone building regulations mean for Aotearoa's community safety and heritage.

JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, “Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.” Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and associate professor at the OU Health Stephenson Cancer Center. Today, we are excited to be joined by Dr. Alison Schram, Associate Attending Physician and Section Head of Oral Therapeutics with Early Drug Development and Gynecologic Medical Oncology Services at the Memorial Sloan Kettering Cancer Center, and the senior author of the JCO Precision Oncology article titled, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Schram, thank you for joining us today. I am excited to be discussing this very interesting, unique topic based on what you published in JCO PO. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: What we like to do for these podcasts is try to make them scientifically interesting but at the same time, keep them at a level where our trainees and other community oncology professionals understand the implications of what you've published. So I'd like to start by asking you, what is leiomyosarcoma for those of us who don't necessarily know a lot about leiomyosarcoma, and what are some of the treatment options for these uterine sarcomas? Dr. Alison Schram: Uterine leiomyosarcoma is a rare subtype of uterine cancer, and it represents about 1% of all female cancers in the reproductive tract. This is a rare malignancy that arises from the myometrial lining of the uterus, and it is generally pretty aggressive. In terms of the standard therapy, the standard therapy for uterine leiomyosarcoma includes chemotherapy, generally combination chemotherapy, but despite a few regimens that tend to be effective, the duration of effectiveness is relatively short-lived, and patients with advanced uterine leiomyosarcoma eventually progress and require additional therapy. I will say that localized uterine leiomyosarcoma can be treated with surgery as well. Dr. Rafeh Naqash: Thank you for that description. Now, there are two aspects to what you published. One is the sarcoma aspect, the leiomyosarcoma, and the second is the BRCA mutation. Since we are a precision medicine journal, although we've discussed BRCA a couple of times before, but again, for the sake of our listeners, could you highlight some of the aspects of BRCA and PARP sensitivity for us? Dr. Alison Schram: Yes. So BRCA is a gene that's important for DNA repair, and BRCA mutations can be either inherited as a germline mutation, so one of your parents likely had a BRCA mutation and you inherited one copy. In patients who have an inherited BRCA mutation, the normal cells tend to have one abnormal copy of BRCA, but if a second copy in the cell becomes altered, then that develops into cancer. And so these patients are at increased risk of developing cancers. Specifically, they are at an increased risk of developing ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and a few others. These cancers are considered BRCA-associated tumors. Alternatively, some patients, more rarely, can develop BRCA-altered cancers completely sporadically. So it's a mutation that happens in the tumor itself, and that can lead to impaired DNA repair and promote cancer progression. And those patients are not, they don't have any inherited risk, but just a random event caused a BRCA mutation in the tumor. The reason this is important is because, in addition to it being potentially important for family members, there are certain treatments that are more effective in BRCA-altered cancers. And the main example is PARP inhibitors, which are small molecule inhibitors that inhibit the PARP enzyme, and there is what we call synthetic lethality. So PARP is important for DNA repair, for single-stranded DNA repair, BRCA is important for double-stranded DNA repair, and in a patient that has a cancer that has a BRCA mutation, that cancer becomes more reliant on single-stranded DNA repair. And if you inhibit it with a PARP inhibitor, the cancer cells are unable to repair DNA, and the cells die. So we call that synthetic lethality. PARP inhibitors are FDA approved in several diseases, predominantly the BRCA-associated diseases I mentioned: breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Dr. Rafeh Naqash: That was very beautifully explained. Honestly, I've heard many people explain BRCA before, but you kind of put it in a very simple, easy to understand format. You mentioned this earlier describing germline or hereditary BRCA and somatic BRCA. And from what I gather, you had a predominant population of somatic BRCA, but a couple of germline BRCA as well in your patient population, which we'll go into details as we understand the study. You mentioned the second hit on the germline BRCA that is required for the other copy of the gene to be altered. In your clinical experience, have you seen outside of the study that you published, a difference in the sensitivity of PARP for germline BRCA versus a somatic BRCA that has loss of both alleles? Dr. Alison Schram: So we will get into what's unique about uterine sarcomas in just a minute. In uterine sarcomas, what we have found is that the BRCA mutations tend to be somatic and not germline, as you mentioned. That is in contrast to the other diseases we mentioned, where the vast majority of these tumors are in patients that have germline BRCA alterations. So one thing that's really unique about the uterine sarcoma population and our paper, I believe, is that it is demonstrating an indication for PARP inhibitors in a population that is not characterized by germline BRCA alterations, but truly these by somatic BRCA alterations. If you look at the diseases that PARP inhibitors are validated to be effective in, including the, you know, the ones I mentioned, the BRCA-associated tumors, there's some data in specific context that suggests that perhaps germline alterations are more sensitive to PARP inhibitors, but that's not universal, and it's really tricky to do because the genetic testing that we have doesn't always tell you if you have two hits or just one hit. So you need more complex genetic analysis to truly understand if there is what we call a biallelic loss. And sometimes it's not a second mutation in BRCA. Sometimes it's silencing of the gene by hypermethylation or epigenetics. Some of our clinical trials are now incorporating this data collection to really understand if biallelic loss that we can identify on more complex genetic testing predicts for better outcomes. And we think it's probably true that the patients that have biallelic loss, whether it be germline or somatic biallelic loss, are more likely to benefit from these treatments. That still needs to be tested in a larger cohort of patients prospectively. Dr. Rafeh Naqash: In your clinical experience, I know you predominantly use MSK-IMPACT, but maybe you've perhaps used some other NGS platforms, next-generation sequencing platforms. Have you noticed that these reports for BRCA alterations the report mentioning biallelic loss in certain cases? I personally don't- I do lung cancer, I do early-phase lung cancer as well, but I personally don't actually remember if I've seen a report that actually says biallelic loss. So after this podcast, I'm going to check some of those NGS reports and make sure I look at it. But have you seen it, or what would be a learning point for the listeners there? Dr. Alison Schram: Exactly. And they usually do not. They usually do not explicitly say, “This looks like biallelic loss,” on the reports. The exception would be if there's a deep deletion, then that implies both copies of the gene have been deleted, and so then you can assume that it's a biallelic loss. But oftentimes, when you see a frameshift alteration or a mutation, you don't know whether or not it's a biallelic loss. And you may be able to get some clues based on the variant allele frequencies, but due to things like whole genome duplication or more complex tumor genomics, it's not clear from these reports, and you really do need a more in-depth bioinformatic analysis to understand whether these are biallelic or not. So that is why I suggest that this really needs to be done in the context of a clinical trial, but there is definitely a theoretical rationale for reporting and treating patients with biallelic losses perhaps more so than someone who has a variant of unknown significance that seems to be monoallelic. The other tricky part, as I mentioned, is the fact that there could be epigenetic changes that silence the second copy, so that wouldn't be necessarily evident on a DNA report, and you would need more complex molecular testing to understand that as well. Dr. Rafeh Naqash: Sure. Now, going to your study, could you tell us what prompted the study, what was the patient population that you collected, and how did you go about this research study design? Dr. Alison Schram: It's actually a great story. I was the principal investigator for a clinical trial enrolling patients regardless of their tumor type to a combination of a PARP inhibitor and immunotherapy. And this was a large clinical trial that was being done as a basket study, as I mentioned, for patients that have either germline or somatic alterations with advanced solid tumors that had progressed on standard therapy. And the hypothesis was that the combination of a PARP inhibitor and immunotherapy would be synergistic and that there would be increased efficacy compared to either agent alone and that patients who had BRCA alterations were a sensitive population to test because of their inherent sensitivity to PARP inhibitors and perhaps their increased neoantigen burden from having loss of DNA repair. So this large study, it's been published, really did show that there was efficacy across several tumor types, but it didn't seem to clearly demonstrate synergy between the immunotherapy and the PARP inhibitor as compared to what you might expect from a PARP inhibitor alone, and in addition to a couple of cases, perhaps attributable to the immunotherapy. So maybe additive rather than synergistic efficacy. However, what really struck me looking at the data was that there were three patients with uterine leiomyosarcoma with BRCA deletions who had the best responses of anyone on the study. So incredible, durable responses. One of my patients with a complete response that continues to not have any evidence of cancer eight years after the initiation of this regimen. And for those of us that treat uterine leiomyosarcoma, this is unheard of. These patients generally, as I mentioned, respond, if they do respond to chemotherapy, it's generally short-lived and the cancer progresses. And so a complete response nearly a decade later turns heads in this field. The other interesting thing was that these uterine leiomyosarcoma patients had somatic alterations rather than a germline alteration with a second hit, and the diseases that are best validated for being responsive to PARP inhibitors include the BRCA-associated diseases, the ones that you're at increased risk for if you have a germline BRCA mutation, including breast, pancreas, prostate, and ovarian. And so it was very interesting that this disease type that seemed to be uniquely sensitive to PARP inhibitors with immunotherapy was also different in that patients with uterine leiomyosarcoma don't tend to have a high frequency of BRCA alterations, and in patients that are born with a BRCA alteration, there doesn't seem to be a clearly increased risk of uterine sarcomas. So this population really jumped out as a uniquely sensitive population that differed from the prior indications for PARP inhibitors. Given this patient and these couple of patients that we observed on the combination, in addition to some other case reports and case series that had started to come out in small numbers, we wanted to look back at our large cohort of patients at Memorial Sloan Kettering to see if we could really get a better sense of the numbers. How many patients at Sloan Kettering with uterine sarcomas have BRCA alterations? Are they generally somatic or germline? Are there unique features about these patients in terms of their clinical characteristics? How many of them have received PARP inhibitors, and if so, is this just luck that these three patients did so well, or is this really a good treatment option for patients with BRCA-altered uterine sarcomas? And so we did this retrospective analysis identifying the patients at Sloan Kettering who met these criteria. So in total, we found 35 patients with uterine sarcomas harboring BRCA alterations, and the majority were leiomyosarcoma, about 86% of them had leiomyosarcoma, which is interesting because there are other uterine sarcomas, but it does seem like BRCA alterations tend to be more often in the leiomyosarcomas. And 13 of these patients with uterine leiomyosarcoma were treated with PARP inhibitors in the recurrent or metastatic setting with about half of those patients having an overall response, so that's a significant tumor shrinkage that sustained, and a clinical benefit rate of 62%. And if we look at the patients that had these BRCA2 deep deletions, which was the patient I had that had this amazing response, the overall response rate jumped to 60% and the clinical benefit rate to 80%. And we defined clinical benefit rate as having maintained on the PARP inhibitor without evidence of progression at six months. So this is really impressive for patients with a difficult to treat disease. And we couldn't do a randomized controlled trial comparing it to chemotherapy, but looking retrospectively at outcomes on chemotherapy studies, this was very favorable, particularly because many of these patients were heavily pretreated. So to get a sense of, you know, how this might compare to chemotherapy, we tried to use patients as their own internal controls, and we looked at how long patients were maintained on the PARP inhibitor as compared to how long they were on the treatment just prior. And we used a ratio of 1.3 to say if they were on the PARP inhibitor for 1.3 times what their previous treatment was or longer, that is pretty clearly better, more of a benefit from that regimen. And the majority of patients did meet that bar. So 58% had a PFS ratio greater than 1.3, and the average PFS ratio was 1.9, suggesting, you know, you would expect the the later lines of therapy to actually not work as well, but this suggests that it's actually working better than the immediately prior line of therapy, to me, suggesting that this is truly a good treatment option for these patients. Dr. Rafeh Naqash: Very interesting. And you mentioned that individuals with tumors having deep deletions were probably more responsive. How did you figure out that there was biallelic loss or deep deletions? Was that part of an extended analysis that was done subsequently? Dr. Alison Schram: So the deletions reported on our report, if it's a biallelic deletion, that is the one biallelic molecular alteration that would be reported. So those are, by definition, biallelic, and I think that that may be one of the reasons that's a good biomarker. But also, what's interesting is that if you have both copies deleted of BRCA, you can't develop reversion mutations. So one of the the known mechanisms of resistance to PARP inhibitors in patients who have BRCA alterations are something called a reversion mutation where, if you have a frameshift alteration, for example, in BRCA that makes BRCA protein nonfunctional, you can develop a second mutation that actually puts the DNA back in frame, and a functional protein is now made. And so a mechanism of resistance to PARP inhibitors is actually reverting BRCA to a wild-type protein, and then BRCA's synthetic lethality no longer makes sense and is no longer effective. But if you've deleted both copies of BRCA, you don't have the ability to restore the function, and you can't develop reversion mutations. And that's perhaps why, you know, my patient and others have had these prolonged responses to PARP inhibitors because you don't have the same ability to develop that mechanism of resistance. Dr. Rafeh Naqash: I remember thinking a year and a half back, I had an individual with prostate cancer and with BRCA2, and using liquid biopsy, I had a reversion mutation that we caught. In your practice, have you seen the utility of doing the serial liquid biopsies in these individuals to catch these reversion mutations? Dr. Alison Schram: Yes, absolutely. And in patients that have the ability to develop a reversion mutation, serial cell-free DNA can catch it, but the caveat is that it doesn't always. So if you see an acquired reversion mutation in cell-free DNA, that can be helpful, particularly if you're planning on putting the patient on another line of therapy that might require a dysfunctional BRCA. So if you're putting them on a clinical trial with a PARP combination and the rationale is that they're sensitive because they don't have a functional BRCA, you would want to know if they developed a reversion mutation, and serial cell-free DNA can definitely identify these reversion mutations. Some of the major clinical trials in ovarian cancer have done serial cell-free DNA and have demonstrated the utility of that approach. The caveat is that some of these reversion mutations are not readily caught on cell-free DNA because they're more complex reversion mutations, or they're not, the part of the gene that develops the reversion mutation is not tiled on the panel. And so it doesn't always catch the reversion mutations. Also, depends on the cell-free DNA shedding, depends on the tumor volume and other factors. And we published a related paper of a patient, it was a really interesting case of a patient with prostate cancer who was on a PARP inhibitor and developed what appeared to be a single reversion mutation on one sample, had negative cell-free DNA, single reversion mutation in a tissue biopsy, and then developed disease progression. And we did an autopsy, and the patient kindly consented to an autopsy, and at the time of autopsy, there were 10 unique reversion mutations identified across 11 metastases. So almost each metastasis had a unique reversion mutation, and only one of them had been seen premortem on a tissue biopsy and not on a cell-free DNA. But that autopsy really drove home to me how much we're missing by doing clinical testing in real time and we really don't know the entire genomic complexity of our patients by doing single samples. And theoretically, cell-free DNA can catch DNA from all the metastases, so you might think that that would be a solution, and it definitely can catch reversion mutations that are not seen in a single biopsy, but you really need to do it all. I mean, you need to do the tissue biopsy sampling, you need to do cell-free DNA, and probably one cell-free DNA test is not enough. Dr. Rafeh Naqash: Thank you, again, for that very nice explanation. Now, one quick provocative question. I remember when I was training, the lab that I used to work in, they used to do a lot of phosphorylation markers for DNA damage response, like phospho NBS, RAD51. Have you seen anything of that sort on these biallelic BRCA mutations where tumors are responding, but they also have a very high signature on the phosphorylation side, and it may or may not necessarily correspond to HRD signatures, but have you noticed or done any of that analysis? Dr. Alison Schram: I think that it would be great to do that analysis. And some of the work we're doing now is actually trying to dig a little bit deeper in our cohort of patients to understand are these HRD-positive tumors? Does HRD positivity correlate with response to BRCA alterations? In terms of the functional assays, I would love to be able to do a functional assay in these samples. One of the challenges is that this was a retrospective study and many of the patients were previously treated as standard of care or off-label with these agents, and so we didn't have prospective tissue collection, and so we're really limited by the tissue that was collected as part of standard of care and the consent forms that the patient signed that allow us to do genomic and molecular testing on their samples. So, I think that is hopefully future work that we will do and others will do. Dr. Rafeh Naqash: Sure. Shifting gears to your career trajectory, I'd like to spend a couple of minutes there before we end the podcast. So Dr. Schram, you've obviously been a trailblazer in this space of drug development, early-phase trials. Can you give us a brief synopsis of your journey and how you've successfully done what you're doing and what are some of the things that drive you? Dr. Alison Schram: Well, thank you for saying that. I don't know if that's true, but I'll take the bait. I've been interested in oncology since college and was always very interested in not only the science of oncology but of course, treating patients. And in medical school, I did basic science research in a laboratory and it was very inspiring and made me want to do research in oncology in addition to clinical care. When I became an oncology fellow, I was presented with a very difficult question, which is, “Do you want to be a lab PI and be in the lab, or do you want to do clinical care and clinical research?” And I couldn't choose. I found a mentor who thankfully really had this amazing vision of combining the two and doing very early drug development, taking the data that was being generated by labs and translating it into patients at the earliest stage. So, you know, phase one drug development in molecularly targeted therapies. And so I became very interested as a fellow in early drug development and this ability to translate brand new molecular insights into novel drugs. And I joined the- at Sloan Kettering, there was the Early Drug Development, it was actually a clinic, it was called something different, and it was very fortuitous. My last year of fellowship, the clinic became its own service with the ability to hire staff at Sloan Kettering, and I was the first ever hire to our Early Drug Development Service. And that really inspired me to try and bring these drugs to patients and to really translate the amazing molecular insights that my colleagues here at Sloan Kettering are discovering, and you know, of course, at other institutions and in pharma. And you know, there 's been an amazing revolution in in drug development over the last several years, and I feel very grateful that I've been here for it. You know, I've been able to take the brilliant insights from my colleagues and put these drugs in patients, and I have the amazing privilege of watching patients in many cases that benefit from these treatments. And so I do mostly phase one drug development and molecularly targeted therapies, and truthfully, I am just very fortunate to be around such brilliant people and to have both patients and labs trust me to be able to deliver these new drugs to patients and hopefully develop better drugs that move forward through FDA approval and reach patients across the country. Dr. Rafeh Naqash: Thank you so much. That was very nicely put. And hopefully our trainees and junior faculty find that useful based on their own career trajectories. Thank you, Dr. Schram, for joining us today. Hopefully, we'll see more of your subsequent work in JCO PO. Thank you for giving us all these insights today. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Alison Schram Disclosures Consulting or Advisory Role Company: Mersana, Merus NV, Relay Therapeutics, Schrodinger, PMV Pharma ,Blueprint Medicines, Flagship Pioneering, Redona Therapeutics, Repare Therapeutics, Endeavor BioMedicines Research Funding Company: Recipient: Your Institution  Merus, Kura, Surface Oncology, AstraZeneca, Lilly, Pfizer , Black Diamond Therapeutics, BeiGene, Relay Therapeutics, Revolution Medicines,  Repare Therapeutics, PMV Pharma, Elevation Oncology, Boehringer Ingelheim Travel, Accommodations, Expenses Company: PMV Pharma 

Business-as-usual this morning as TDS sufferers freak about the President, his interview w/ NBS's Kristen Welker being the chief trigger. And then there's that little thing about the Pope.